A new study funded by Amgen Inc. finds that the company's PCSK9 inhibitor Repatha is cost effective at the annual net price of $9,669, though an editorial accompanying the study questions whether the findings are based on "best-case scenarios" and feeds into a familiar refrain that the class still costs too much.
Results from the cost-effectiveness study were published by investigators from Amgen's FOURIER outcomes study of Repatha (evolocumab) in the Journal...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?